SAB4200695

Anti-VSV Glycoprotein antibody, Mouse monoclonal

Name: Anti-VSV Glycoprotein antibody, Mouse monoclonal
Brand: SIGMA

clone P5D4, purified from hybridoma cell culture

Synonym(s):

VSV, VSV glycoprotein, Vesicular Stomatitis Virus glycoprotein

Select a Size

All Photos(2)

About This Item

NACRES:

NA.46

UNSPSC Code:

12352203

Product Name

Anti-VSV Glycoprotein antibody, Mouse monoclonal, clone P5D4, purified from hybridoma cell culture

biological source

mouse

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

P5D4, monoclonal

form

buffered aqueous solution

species reactivity

virus (Vesicular stomatitis virus (VSV))

packaging

antibody small pack of 25 μL

concentration

~1 mg/mL

technique(s)

immunoblotting: 0.5-1 μg/mL using whole extract of human HEK-293T cells over-expressing Vinculin with VSV-G tagged fusion protein.
immunocytochemistry: suitable
immunofluorescence: 5-10 μg/mL using COS7 cells over-expressing Vinculin with VSV-G tagged fusion protein.
immunoprecipitation (IP): suitable

isotype

IgG1

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

200

Application

Anti-VSV Glycoprotein antibody, Mouse monoclonal has been used in immunoblotting, immunofluorescence, immunoprecipitation, immunocytochemistry, transmission electron microscopy (TEM) and studies applying microinjection of the antibody.

Biochem/physiol Actions

Vesicular Stomatitis Virus Glycoprotein (VSV-G) constitutes an attractive model to study maturation and intracellular transport of membrane proteins. It mediates attachment of VSV to the cell surface and induces pH-dependent fusion between viral and target membranes. In addition, it possesses information for intracellular sorting in its cytoplasmic domain, including efficient export from the endoplasmic reticulum (ER), basolateral delivery and endocytosis. The unidirectional transport between golgi cisternae was demonstrated using golgi membranes containing VSV-G. Temperature sensitive mutants of VSV-G are used to study exit of folding intermediates from the endoplasmic reticulum.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Anti-VSV Glycoprotein antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the hybridoma P5D4 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide of Vesicular Stomatitis Virus Glycoprotein (VSV-G), conjugated to KLH.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Not finding the right product?

Try our Product Selector Tool.

Storage Class

12 - Non Combustible Liquids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The BCL-2 family protein BCL-RAMBO interacts and cooperates with GRP75 to promote its apoptosis signaling pathway.

Jinghong Xu et al.

Scientific reports, 13(1), 14041-14041 (2023-08-29)

The BCL-2 family protein BCL-RAMBO, also known as BCL2-like 13, anchors at the outer mitochondrial membrane and regulates apoptosis, mitochondrial fragmentation, and mitophagy. However, the mechanisms underlying the proapoptotic role of BCL-RAMBO remain unclear. In the present study, we demonstrated

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.

Karen Geoffroy et al.

Molecular therapy. Oncology, 32(3), 200826-200826 (2024-07-15)

Therapy-resistant ovarian cancers have a poor prognosis and novel effective treatment options are urgently needed. In this study, we evaluated the therapeutic efficacy of the oncolytic vesicular stomatitis virus (VSV) against a panel of patient-derived ovarian cancer cell lines of

p38: A novel protein that associates with the vesicular stomatitis virus glycoprotein

Sevier CS and Machamer CE

Biochemical and Biophysical Research Communications, 287(2), 574-582 (2001)

Auto-regulation of secretory flux by sensing and responding to the folded cargo protein load in the endoplasmic reticulum

Subramanian A, et al.

Cell, 176(6), 1461-1476 (2019)

The Dual-Pseudotyped Lentiviral Vector with VSV-G and Sendai Virus HN Enhances Infection Efficiency through the Synergistic Effect of the Envelope Proteins.

Bat-Erdene Jargalsaikhan et al.

Viruses, 16(6) (2024-06-27)

A gene delivery system utilizing lentiviral vectors (LVs) requires high transduction efficiency for successful application in human gene therapy. Pseudotyping allows viral tropism to be expanded, widening the usage of LVs. While vesicular stomatitis virus G (VSV-G) single-pseudotyped LVs are

View All Related Papers